Delayed administration of antibiotics and mortality in patients with community-acquired pneumonia

Annals of Emergency Medicine
Allen C Cheng, Kirsty L Buising

Abstract

Previous studies have demonstrated a crude association between the time to first antibiotic dose and mortality in patients with community-acquired pneumonia. We hypothesize that time to first antibiotic dose may affect mortality, particularly for patients at high risk of death, that is, patients hypoxic on presentation, patients in Pneumonia Severity Index class IV or V, and patients older than 65 years at our institution. We reviewed data from a prospectively collected database of patients with community-acquired pneumonia, excluding patients who had received antibiotics before presentation and palliative patients not receiving antibiotics. We examined time to first antibiotic dose in patients who died or had prolonged length of stay (all patients) and in specific subgroups regarded as high risk (age >65 years, Pneumonia Severity Index class IV or V, presence of hypoxia or hypotension). In 501 patients, the median time to first antibiotic dose was 2.7 hours, with 91% of patients receiving antibiotics within 8 hours. Time to first antibiotic dose was not positively associated with mortality or prolonged length of stay in any of the subgroups examined. We found evidence that patients with severe pneumonia received antibiotics ea...Continue Reading

References

Dec 24, 1997·JAMA : the Journal of the American Medical Association·T P MeehanJ M Fine
Sep 29, 2007·Critical Care Medicine·Stijn I BlotUNKNOWN Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators
Oct 9, 2007·Emergency Medicine Australasia : EMA·Kirsty L BuisingGraham V Brown
Feb 27, 2008·Archives of Internal Medicine·James A WelkerJack D McCue
Apr 19, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Patrick G P CharlesUNKNOWN Australian CAP Study Collaboration

❮ Previous
Next ❯

Citations

Mar 19, 2011·Clinical Medicine : Journal of the Royal College of Physicians of London·Thomas BewickWei Shen Lim
May 7, 2011·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·Erin QuattromaniD Mark Courtney
Jun 2, 2011·Respirology : Official Journal of the Asian Pacific Society of Respirology·Tom Kotsimbos, Allen C Cheng
Nov 26, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A SimonettiJ Carratalà
Jan 6, 2016·Antimicrobial Agents and Chemotherapy·Kimberly C ClaeysMichael J Rybak
Jan 21, 2010·Expert Opinion on Pharmacotherapy·Stavros Anevlavis, Demosthenes Bouros
Mar 26, 2010·Critical Care Medicine·Shelly ZubertAnand Kumar
May 28, 2017·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Kathleen MorneauKaty M Toale

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.